ArticleNature communications2024
Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Weekly azithromycin for 48 weeks impacts nasopharyngeal microbial prevalence and Streptococcus pneumoniae serotypes in children with HIV-associated chronic lung disease.Scientific reports · 2025Trial
- Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis.Human vaccines & immunotherapeutics · 2026Article
- Pneumococcal population structure influences the effects of air pollution on invasive disease risk in South Africa.Nature microbiology · 2026Article
- Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa.Microbial genomics · 2026Article
- Genomic analysis ofMicrobial genomics · 2026Article
- Fourteen-year genomic surveillance of pediatric invasive Streptococcus pneumoniae: genomic and pan-genomic characterization.BMC microbiology · 2026Article
- What is driving the resurgence and persistence of vaccine-targeted pneumococcal serotypes?-Serotype 19F as the paradigm.PLoS pathogens · 2026Review
- Lineage structure and penicillin-binding protein variability in clinicalFrontiers in public health · 2026Article
- Pneumococcal conjugate vaccines and antimicrobial resistance: serotype replacement, clonal dynamics, and future vaccine perspectives.Frontiers in immunology · 2026Review
- Article
- Article
- Population snapshot ofMicrobial genomics · 2025Article
- Genomic surveillance of invasiveMicrobial genomics · 2025Article
- Genomic analysis of invasive and non-invasive disease-causingMicrobial genomics · 2025Article
- Review
- Investigating two decades ofMicrobial genomics · 2025Article
- SeqAfrica: empowering Africa's fight against antimicrobial resistance through genomics.Frontiers in public health · 2025Article
- Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Invasive pneumococcal disease (IPD) due to non-vaccine serotypes after the introduction of pneumococcal conjugate vaccines (PCV) remains a global concern. This study used pathogen genomics to evaluate changes in invasive pneumococcal lineages before, during and after vaccine introduction in South Africa. We included genomes (N = 3104) of IPD isolates from individuals aged <18 years (2005-20), spanning four periods: pre-PCV, PCV7, early-PCV13, and late-PCV13. Significant incidence reductions occurred among vaccine-type lineages in the late-PCV13 period compared to the pre-PCV period. However, some vaccine-type lineages continued to cause invasive disease and showed increasing effective population size trends in the post-PCV era. A significant increase in lineage diversity was observed from the PCV7 period to the early-PCV13 period (Simpson's diversity index: 0.954, 95% confidence interval 0.948-0.961 vs 0.965, 0.962-0.969) supporting intervention-driven population structure perturbation. Increases in the prevalence of penicillin, erythromycin, and multidrug resistance were observed among non-vaccine serotypes in the late-PCV13 period compared to the pre-PCV period. In this work we highlight the importance of continued genomic surveillance to monitor disease-causing lineages post vaccination to support policy-making and future vaccine designs and considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.